20 research outputs found
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
Introduction: In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin,
vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell
therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not
candidates for autologous stem cell therapy. Options may include palliative regimens or clinical trial enrollment.
One therapy under investigation in diffuse large B-cell lymphoma is lenalidomide, an immunomodulatory agent
with antiangiogenic activity.
Case presentation: We present the case of a 55-year-old Caucasian male patient diagnosed with diffuse large B-cell
lymphoma who had an early relapse after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone. He then had a subsequent early relapse after cisplatin-based salvage consolidated with autologous
stem cell therapy. The efficacy of gemcitabine-cisplatin-rituximab was limited to five months, followed by
systemic and central nervous system progression. Fourth-line treatment with lenalidomide plus rituximab and
involved-field radiotherapy followed by lenalidomide monotherapy greatly improved this patient’s quality of life
and performance status, allowing over two years of progression-free survival to date (excluding a brief relapse
due to treatment interruption).
Conclusion: A lenalidomide-based regimen was highly effective in this patient with diffuse large B-cell lymphoma
Basin effects on ground motion: the case of a high-resolution experiment in Cephalonia (Greece)
International audienc